Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report-Reference-Cited by-同舟云学术

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report

Published:2020-06 Issue:28 Volume:38 Page:4476-4483
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Capeding Maria Rosario,Alberto Edison,Sil Arijit,Saluja Tarun,Teshome Samuel^ORCID,Kim Deok Ryun,Park Ju Yeon,Yang Jae Seung,Chinaworapong Suchada,Park Jiwook,Jo Sue-Kyoung,Chon Yun,Yang Seon-Young,Ham Dong Soo,Ryu Ji Hwa,Lynch Julia,Kim Jerome H.,Kim Hun,Excler Jean-Louis,Wartel T. Anh,Sahastrabuddhe Sushant

Funder

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference34 articles.

1. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis;John;PLoS Negl Trop Dis.,2016

2. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017;Lancet Infectious Dis,2019

3. Blood culture confirmed typhoid fever in a provincial hospital in the Philippines;Abucejo;Southeast Asian J Trop Med Public Health,2001

4. GOVPH. Department of Health. 2018 Typhoid Morbidity Week 52. Available at: (Accessed in April 2019).

5. Background Paper on Typhoid Vaccines for SAGE Meeting (October 2017) . accessed 22nd February 2019.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Typhoid Conjugate Vaccine: A Boon for Endemic Regions;Cureus;2024-03-19

2. Typhoid Fever Vaccines;Plotkin's Vaccines;2023

3. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants;Vaccine;2022-09

4. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age;The Lancet Regional Health - Western Pacific;2022-07

5. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose;npj Vaccines;2022-01-27